SELLAS Life Sciences Announces Update on Phase III REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. announced important updates relating to its ongoing Phase III open-label registrational clinical trial for galinpepimut-S in acute myeloid leukemia patients who have achieved complete remission following second-line salvage therapy.